ARTICLE | Emerging Company Profile
Eyebiotech launches with $65M for experienced ophthalmology team
Eyebiotech targets multispecific, long-acting assets for eye diseases
February 23, 2022 12:20 AM UTC
A syndicate of blue-chip VCs is backing a management team of repeat entrepreneurs to build a next-generation pipeline of ophthalmic therapies using the U.K.’s established clinical trial and manufacturing infrastructure.
Eyebiotech Ltd. announced Tuesday that it raised a $65 million series A round co-led by SV Health Investors, Jeito Capital and Samsara BioCapital. MRL Ventures also participated...